NSE: ERIS | BSE: 540596

Mid-range Performer

Download real time

1675.90 -23.30 (-1.37%)

High volume today

NSE 12 Sep, 2025 3:31 PM (IST)

22,828

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Eris Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ERIS, BSE:540596 Eris Lifesciences Ltd.

Eris Lifesciences Ltd.

12 Apr 2018, 12:00AM

1675.90

-1.37%

ERIS LIFESCIENCES LTD

Buy: Eris Lifesciences Ltd.

Ventura

We initiate coverage on Eris as a BUY with a price target of Rs 1,060,

Eris Lifesciences Ltd. has an average target of 1581.00 from 3 brokers.

Eris Lifesciences Ltd.

27 Nov 2017

1675.90

-1.37%

Result Update:ERIS Lifescience

Buy: Eris Lifesciences Ltd.

Target

Axis Direct

Q2FY18 EBITDA grew 32% YoY (~15% above our estimate) led by 25% YoY growth in topline (15% YoY on standalone basis). EBITDA margin improved 210 bps YoY driven by operating leverage.

Promoters unpledged 1.58% of shares in last quarter. Total pledge stands at 16.93% of promoter holdings

Eris Lifesciences Ltd.

22 Nov 2017

1675.90

-1.37%

ERIS LIFESCIENCES LIMITED

IPO Note: Eris Lifesciences Ltd.

Geojit Research

Eris Lifesciences Ltd (ELL) is a developer cum manufacturer of branded pharmaceutical products in select therapeutic areas of cardiovascular, anti-diabetics, vitamins, gastroenterology and anti-infectives. Company's product portfolio comprises of 80 mother brand groups with the top 10 brands contributing as much as 75% of their total revenues. ELL is primarily focusing on lifestyle diseases encompassing both the chronic (65%) and acute segments(35%). They are currently the fastest growing company among the top 25 players in the chronic segment. It...

Eris Lifesciences Ltd. is trading below its 30 day SMA of 1746.4

Eris Lifesciences Ltd.

26 Oct 2017

1675.90

-1.37%

Eris Life

Buy: Eris Lifesciences Ltd.

Bonanza

Recently, the stock price of Eris Lifesciences Ltd. (Eris) corrected by ~22 from 52-week high of Rs.728 as the company has reported below expected numbers in the recent quarters. Eris focuses on lifestyle related disorders, which are chronic in nature. Hence, the main target of the company is specialist and super specialist doctors. It is mainly into select therapeutic areas, such as, CVS, antidiabetics, vitamins, gastroenterology, anti-infectives and gynecology. In FY17, chronic segment generated 66% of total revenues. Even in the acute segment (34% of total revenues), the company focuses on...

Eris Lifesciences Ltd. has gained 32.16% in the last 6 Months

Eris Lifesciences Ltd.

23 Aug 2017

1675.90

-1.37%

Company Report - Eris Lifesciences

Buy: Eris Lifesciences Ltd.

Axis Direct

Eris has a unique positioning in the India Pharma market. It is 100% into domestic formulations and the 2nd fastest growing (22% CAGR % over FY13-17) among the top 35 pharma companies in India. Eris is ranked 32nd despite being a relatively new entrant (established in 2007).

Eris Lifesciences Ltd. is trading above its 200 day SMA of 1497.5

Eris Lifesciences Ltd.

16 Jun 2017

1675.90

-1.37%

Eris Lifesciences Ltd - IPO Note

IPO Note: Eris Lifesciences Ltd.

Systematix Group

Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders: Eris has Develop, Manufacture and Commercialize branded prescription based pharmaceuticals products in select chronic and acute therapeutic areas, like Cardiovascular, Anti-Diabetics, Vitamins, Gastroenterology, Anti-Infectives, & Gynaecology. In FY17, they generated 65.6% of their revenues from the chronic category of the IPM. The chronic category accounted for 34.3% of the IPM in FY17 compared to 31.4% of the IPM in FY13, representing growth at a CAGR of 14.3%. They have identified, developed and are marketing products in the acute category, which are connected to...

Eris Lifesciences Ltd. has gained 32.16% in the last 6 Months

Eris Lifesciences Ltd.

15 Jun 2017

1675.90

-1.37%

HDFC sec IPO Note Eris Lifesciences Ltd

IPO Note: Eris Lifesciences Ltd.

HDFC Securities

Eris Lifesciences Ltd Issue Open: June 16 - June 20 2017, Price Band: Rs. 600 - 603

Eris Lifesciences Ltd. is trading at high day volume of 711.9K.

Eris Lifesciences Ltd.

15 Jun 2017

1675.90

-1.37%

IPO Update - Eris Lifesciences Ltd.

IPO Avoid: Eris Lifesciences Ltd.

Choice India

Eris Lifesciences Ltd. (ELL) is a developer, manufacturer and commercializer of branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM....

Eris Lifesciences Ltd. is trading above its 200 day SMA of 1497.5

Eris Lifesciences Ltd.

15 Jun 2017

1675.90

-1.37%

Eris Lifescience Ltd IPO Note Subscribe 14th June

IPO Subscribe: Eris Lifesciences Ltd.

BP Wealth

Eris Lifesciences Ltd is an Ahmedabad, Gujarat based pharmaceutical company, incorporated in 2007 that is engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market. Company's focus has been on developing, manufacturing and marketing products, which are linked to lifestyle related disorders that are chronic in nature and to a target population which primarily consults specialists and superspecialists. Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics). In acute category, the product portfolio includes vitamins, gastroenterology, antiinfectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing. The product portfolio of the company comprised of 80 Mother Brand Groups as of March 31, 2017. It also owns and...